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PerspectivesAbstract Among the neurodegenerative diseases, Alzheimer’s disease (AD) represents one of the
biggest challenges that the modern health care system has to deal with. The lack of data about
the etiology and the complexity of the underlying pathogenesis constitute the biggest struggle facing
the development of new therapeutical approaches. Within this paper we describe selected currently
used approaches, point some challenges and give indications about the future perspectives in AD
treatments. We hope this paper together with the selected references will contribute in putting spot
light on the future of AD therapies and give guidelines for both professionals and researches work-
ing on that area of the brain diseases.
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One of the major challenges facing the modern health care
system is the neurodegenerative diseases such as Alzheimer’s
disease (AD)1 that represents the most prevalent dementia.1
AD represents a neurodegenerative disorder characterized by
loss of neurons, cognition2 and a progressive loss of brain
2 A. Ghanemifunctions.3 This disorder affects a large number of the human
population, for instance in USA alone more than 5 million
people suffer from AD.4 AD has heavy medical, economic
and social consequences due not only to AD itself but also
due to the related problems such as dementia, both depen-
dency and disability among older people5 and vascular
impairment.6
Although the AD-related neurodegenerative process
remains unclear,7 description of some pathogenic processes
has been reported. AD is associated with the aggregation of
abnormal proteins2 including amyloid beta (Ab)protein5,8 that
aggregate into senile plaques9 in the brains of AD patients8
and the pathologically modiﬁed tau9 which are hyperphospho-
rylated5 and that aggregate into neuroﬁbrillary tangles9 in the
brain. Both neurons’ death and amyloid protein ﬁbril accumu-
lation lead to AD10 and the accumulation of Ab in the brain
leads to a chain of pathogenic processes n brains of AD
patients.11
Furthermore, other phenomena have been reported as parts
of the AD pathological process including altered synaptic
function,12 Cerebral amyloid angiopathy13 and functional
and morphological impairment of cerebral circulation.6
Importantly, neuroinﬂammation is also a key element within
AD pathogenesis.14 Theses diverse elements reﬂect the differ-
ent targets we can consider for AD therapeutic approaches.
2. Selected therapeutic advances
At present, current drug treatments of AD, such as cholines-
terase inhibitors or NMDA antagonists,1 mainly help to man-
age symptoms5 hereby obviating the need for new approaches
to deal with AD underlying mechanisms. Indeed, some current
therapeutic approaches include reversible cholinesterase inhib-
itor like rivastigmine.2
Epidemiological studies have important contributions to
presenting new bases for future. For instance, risks of develop-
ing Alzheimer’s disease can be decreased by smoking tobacco
and it was suggested that nicotine inhibits neuronal apoptosis
which prevents the Ab25–35-induced neurotoxicity15 pointing
a starting point to new therapeutic approaches.
Natural products described by pharmacognosy constitute
important resources for AD treatment especially after modern
sciences have built bridges between Traditional Chinese Med-
icines and modern pharmacology.16 For instance, Malay tradi-
tional practitioners claimed that Aquilaria subintegra leaves
can treat AD patients, supposedly via Acetyl choline inhibi-
tion17 and the amyloid formation could be inhibited by Silym-
arin which is a standardized extract of milk thistle.18 In
addition, since inﬂammation is an element within AD patho-
genesis14, extracts or compounds from plants with anti-Inﬂam-
matory properties such as Nigella glandulifera Freyn et Sint19
could provide a complementary therapy.
Importantly, different ﬁndings and ways for research
deserve more attention. Molecules that inhibit Amyloid-b such
as pinocembrin,11 emerging therapeutic targets for the treat-
ment of AD including Glucagon-like peptide-114 represent
good examples. Moreover, both the development of animal
models of AD20 and the description of molecules implicated
in diverse pathogenesis such as cyclic peptides10 and the Ab-
targeted immunotherapy5 and cysteinyl leukotriene receptor
1 antagonism21 sphingosine 1-phosphate receptor22 5-HT4receptor-induced a-secretase activation23 bring more hope
toward identifying new targets.
3. Perspectives and challenges
The new methods including ultrasound6 and positron emission
tomography24 help for the early AD diagnosis. Furthermore,
they allow us to follow the disease evolution during treatment
and potentially identify new therapeutic targets. Indeed, AD
development may be related to metabolic disorders like type-
2 diabetes mellitus, insulin resistance, metabolic syndrome
and obesity.25 Moreover, Epidemiological data15,25 diverse tra-
ditional medicines,17 animal studies25 and the recent investiga-
tions about AD cellular and molecular aspects5 also provide
strong starting points to develop new therapeutic approaches
for AD.
Diverse approaches are under investigation and some have
already shown promising results in AD patients. The immuno-
therapies that increase Ab accumulation in preclinical models5
and metabolic-based therapies25 represent good examples. We
should extend our ﬁelds of thinking beyond antiamyloid ther-
apy for AD.26 Indeed, Tau-related immunotherapy is expected
to see further development toward clinical trials5 as emerging
therapeutic strategies for both tauopathies and AD.1 Another
example for AD treatment is the metal chelation; as metal
binding with Ab has been described.8 Further approaches to
prevent spine degeneration in AD12 seem urgent. At the same
time research about AD must take into consideration the
parameters that could inﬂuence the AD risks, pathogenesis5
or prognosis including Patient’s gender.4
However, AD researches still need to overcome different
struggles including the regulations and the legal aspects27
and the fact that different therapeutic theories require
in vivo and biodistribution studies2 before we see a speed up
in the progress of AD researches.Conﬂict of interest
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